About Dompé
Dompé farmaceutici S.p.A. is a global bio-pharmaceutical company with 130 years of experience partnering with medical centers and universities to advance science-driven innovations. We are committed to research programs aimed at validating new targets for the treatment of rare diseases.
Within our NETosis platform, we are focused on identifying and understanding mechanisms involved in the immune response to pathogenic challenges. Amongst these mechanisms, NETosis consists in the entrapment of pathogenic microbes/molecules by extracellular proteins and DNA fragments secreted by neutrophil cells and plays a master role in the development and progression of inflammation. Chemokines are critical in the process of NETosis as they are responsible for recruiting neutrophils to the site of inflammation. At Dompé, we are screening novel drugs targeting culprit chemokines to inhibit pathogenic NETosis. For more information about our NETosis Pipeline Clinical Trials, please visit https://www.dompe.com/science/netosis
Our clinical studies are conducted in full compliance with Good Clinical Practice (GCP) international guidelines, and with a passion for people in need. Data from our studies can be accessed on a number of public databases, including www.clinicaltrials.gov.
Thank you for taking the time to learn more about this study. Without the partnership of the healthcare community, of which you are a vital part, we could not bring innovative therapies to patients who have the greatest need.